About Procyon Pharmeceuticals
Procyon Pharmecuticals, Inc. is an veterinary pharmecutical research and development company with a robust, theraputically diverse pipeline of products being developed to meet the needs of veterinarians and pet owners.
Procyon Pharmeceuticals Frequently Asked Questions (FAQ)
Where is Procyon Pharmeceuticals's headquarters?
Procyon Pharmeceuticals's headquarters is located at Madison.
What is Procyon Pharmeceuticals's latest funding round?
Procyon Pharmeceuticals's latest funding round is Incubator/Accelerator.
Who are the investors of Procyon Pharmeceuticals?
Investors of Procyon Pharmeceuticals include MGE Innovation Center.
Who are Procyon Pharmeceuticals's competitors?
Competitors of Procyon Pharmeceuticals include Trillium Therapeutics, Ambitech Engineering, Provepep, iPierian, Akebia Therapeutics and 11 more.
Compare Procyon Pharmeceuticals to Competitors
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
We are a biopharmaceutical company developing and commercializing therapies for vascular disorders. Our research and development efforts are focused on therapies for stroke and other vascular disorders, using our proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. In addition to the brain and the lungs, blood clots can block blood flow and cause damage to other tissues in the body such as the heart, in case of coronary arterial disease, and the legs and other extremities, in case of peripheral vascular disease. We believe our development and research stage products may address significant unmet medical needs not only for stroke but also for clot-induced damage in tissues other than the brain.
CSEM, the Swiss Center for Electronics and Microtechnology, is a research and development company active in applied research, product development, prototype and low-volume production, and technology consulting. Its main fields of activity are micro- and nanotechnologies, microelectronics, systems engineering, microrobotics, photonics, information and communication technologies.
Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.
Fermalogic is engaged in industrial microbiology research and development with specialization in genetic engineering of fermentation microorganisms for the development of new pharmaceutical products and process improvement.
Occam BioLabs is a company engaged in developing technologies for detection and quantification of biomolecules. The company is focused on three general areas of research and development: design and prototyping of electro-optical devices for analysis of biological samples, developing analytic reagents and kits for emergent biomedical fields, providing expertise services for assay optimization including high-throughput quantification in the pharmaceutical industry.